IRIS Accounts Production v23.2.0.158 12361382 director 1.7.22 30.6.23 30.6.23 26/9/23 false true false false true false Auditors Opinion Ordinary share 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure123613822022-06-30123613822023-06-30123613822022-07-012023-06-30123613822021-06-30123613822021-07-012022-06-30123613822022-06-3012361382ns16:EnglandWales2022-07-012023-06-3012361382ns15:PoundSterling2022-07-012023-06-3012361382ns11:Director12022-07-012023-06-3012361382ns11:PrivateLimitedCompanyLtd2022-07-012023-06-3012361382ns11:SmallEntities2022-07-012023-06-3012361382ns11:Audited2022-07-012023-06-3012361382ns11:SmallCompaniesRegimeForDirectorsReport2022-07-012023-06-3012361382ns11:SmallCompaniesRegimeForAccounts2022-07-012023-06-3012361382ns11:FullAccounts2022-07-012023-06-3012361382ns11:OrdinaryShareClass12022-07-012023-06-3012361382ns11:CompanySecretary12022-07-012023-06-3012361382ns11:RegisteredOffice2022-07-012023-06-3012361382ns6:CurrentFinancialInstruments2023-06-3012361382ns6:CurrentFinancialInstruments2022-06-3012361382ns6:Non-currentFinancialInstruments2023-06-3012361382ns6:Non-currentFinancialInstruments2022-06-3012361382ns6:ShareCapital2023-06-3012361382ns6:ShareCapital2022-06-3012361382ns6:RetainedEarningsAccumulatedLosses2023-06-3012361382ns6:RetainedEarningsAccumulatedLosses2022-06-3012361382ns6:PlantMachinery2022-07-012023-06-3012361382ns6:PlantMachinery2022-06-3012361382ns6:PlantMachinery2023-06-3012361382ns6:PlantMachinery2022-06-3012361382ns6:WithinOneYearns6:CurrentFinancialInstruments2023-06-3012361382ns6:WithinOneYearns6:CurrentFinancialInstruments2022-06-3012361382ns11:OrdinaryShareClass12023-06-30
REGISTERED NUMBER: 12361382 (England and Wales)


















AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2023

FOR

INVEX THERAPEUTICS LTD

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3 to 5


INVEX THERAPEUTICS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 30 JUNE 2023







DIRECTOR: Mr A N C Eastman



SECRETARY: Oakwood Corporate Secretary Limited



REGISTERED OFFICE: Eccleston Yards
25 Eccleston Place
London
SW1W 9NF



REGISTERED NUMBER: 12361382 (England and Wales)



SENIOR STATUTORY AUDITOR: Benjamin Furness



AUDITORS: Allens Accountants Limited
Registered Auditors and
Chartered Accountants
123 Wellington Road South
Stockport
Cheshire
SK1 3TH

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

BALANCE SHEET
30 JUNE 2023

30/6/23 30/6/22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 2,209 2,805

CURRENT ASSETS
Debtors 5 802,286 314,751
Cash at bank 62,276 91,018
864,562 405,769
CREDITORS
Amounts falling due within one year 6 591,283 204,867
NET CURRENT ASSETS 273,279 200,902
TOTAL ASSETS LESS CURRENT
LIABILITIES

275,488

203,707

CREDITORS
Amounts falling due after more than one
year

7

4,801,936

1,560,258
NET LIABILITIES (4,526,448 ) (1,356,551 )

CAPITAL AND RESERVES
Called up share capital 8 1 1
Retained earnings (4,526,449 ) (1,356,552 )
SHAREHOLDERS' FUNDS (4,526,448 ) (1,356,551 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 26 September 2023 and were signed by:





Mr A N C Eastman - Director


INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2023

1. STATUTORY INFORMATION

Invex Therapeutics Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 6 (2022 - 5 ) .

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2023

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 July 2022 4,674
Additions 1,049
At 30 June 2023 5,723
DEPRECIATION
At 1 July 2022 1,869
Charge for year 1,645
At 30 June 2023 3,514
NET BOOK VALUE
At 30 June 2023 2,209
At 30 June 2022 2,805

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/6/23 30/6/22
£    £   
Other debtors 802,286 314,751

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30/6/23 30/6/22
£    £   
Trade creditors 583,678 67,228
Taxation and social security - 1
Other creditors 7,605 137,638
591,283 204,867

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
30/6/23 30/6/22
£    £   
Amounts owed to group undertakings 4,801,936 1,560,258

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 30/6/23 30/6/22
value: £    £   
1 Ordinary share £1 1 1

INVEX THERAPEUTICS LTD (REGISTERED NUMBER: 12361382)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 JUNE 2023

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Benjamin Furness (Senior Statutory Auditor)
for and on behalf of Allens Accountants Limited

10. ULTIMATE PARENT COMPANY

The largest group in which the results are consolidated is that headed by its immediate and ultimate holding company, Invex Therapeutics Ltd., incorporated and registered in Australia.